SkipToContent
HeaderPhoneNumberLabel+1 215 942 8226
Subscriber Login
LanguageSelector
Select...
Sentio Protect and MedAire partnership banner

Press announcement

MedAire and SENTIO Protect Partner for Onboard COVID-19 Testing with Travel Certification

MedAire, the world’s leading superyacht medical assistance provider and SENTIO Protect, specialist consultants in COVID-19 superyacht response technologies, today announced an important partnership which appoints MedAire as SENTIO’s exclusive partner for their onboard molecular testing solution for the superyacht industry, increasing the options available for vessels in setting up their own onboard testing programme.

Ribbon

MedAire, the world’s leading superyacht medical assistance provider and SENTIO Protect, specialist consultants in COVID-19 superyacht response technologies, today announced an important partnership which appoints MedAire as SENTIO’s exclusive partner for their onboard molecular testing solution for the superyacht industry, increasing the options available for vessels in setting up their own onboard testing programme.

Powered by the cue health genetic testing platform, the solution uses molecular NAAT Nucleic Acid Amplification Test (commonly known as PCR) and it only requires a non-invasive, lower nasal swab to test for SARS‑CoV‑2 presenting results in under 20 minutes, with 99% Sensitivity and 98% Specificity across 4 clinical trials.

The solution also gives superyachts the ability to generate COVID-19 certification for international pre-departure travel without having to leave their vessel, with regulatory approval under U.S. FDA EUA, Health Canada, EU CE IVD Directive and CDSCO India.

In addition the technology has been successfully validated in detecting the new Omicron Variant of Concern.

Sentio Protect and MedAire partnership banner

Steven Bates, MedAire General Manager, says that

The cue health device and solution is ideal for the superyacht environment, as it is compact and very simple for crew members to learn to use.

The device complements MedAire’s existing range of COVID-19 testing options and with low set-up costs, it has already proven an attractive proposition for many of our clients, serving the dual-purpose of mitigating the risk of infection as well as facilitating any required COVID-19 documentation to travel between countries.

James Hammond CEO of the SENTIO Group considers the partnership a perfect fit and envisions the mobile genetic technology taking onboard crew health to another level.

Both MedAire and ourselves have a shared vision for greater protection against Covid-19 and the longer term application for monitoring health. We are developing the platform for the maritime sector with the manufacturer and through 2022 there will be additional genetic tests coming online to use with the reader, including other respiratory viruses, cardiac markers, cholesterol, pregnancy and many more.

To find out more about the solution click here.


For further information contact:
Luc Hill
Senior Marketing Executive, MedAire
m +44 (0)7587 627 811
Email: luc.hill@medaire.com